Navigation Links
Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
Date:4/28/2011

BETHLEHEM, Pa., April 28, 2011 /PRNewswire/ -- Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Celanese EVA Performance Polymers, a leading supplier of ethylene vinyl acetate (EVA) into pharmaceutical applications, are working together to streamline the development of drug-eluting devices.  Building on years of collaboration, Particle Sciences and Celanese EVA Performance Polymers are working to provide Particle Sciences with preferred access to VitalDose™ EVA polymer in early stage projects.  

According to Andrew Loxley, Particle Sciences' Director of New Technologies, "With combination products, devices that deliver drugs, there are multiple parties involved including the innovator, the API supplier, the development group and the polymer supplier.  All parties want to ensure a quality product.  Particle Sciences and Celanese EVA Performance Polymers have been collaborating for a number of years and, because of that relationship, are now in a position to expedite the process."

With this collaboration, there is a highly streamlined process by which Particle Sciences obtains access to use Celanese EVA polymers in early development efforts.  Jamie Beggs, Marketing Development Manager, Celanese EVA Performance Polymers, states, "We are committed to becoming the premier EVA excipient producer and have been providing EVA technology for medical applications for years.  Our VitalDose brand delivers the reliable performance required for pharma applications combined with in-depth technical expertise and comprehensive regulatory knowledge.  This partnership is a testament to the degree to which we have developed confidence in Particle Sciences' capabilities and their focus on quality.  With their capabilities in prototyping, characterization, experience with controlled and highly potent substances and cGMP facilities, they have consistently delivered innovation to our customers."

Robert Lee, Vice President Pharmaceutical Development at Particle Sciences adds, "Combination products have unique development challenges.  For each project, it's important that we start with an open mind as to polymer choice and device architecture.  For our EVA needs, we are extremely pleased to be aligned with Celanese EVA Performance Polymers, the group we believe to be most appropriately addressing this market."

Particle Sciences Inc. is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery.  Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.

Celanese EVA Performance Polymers Inc. is a North American leader in developing products and application technology to improve performance, create value and drive innovation in a broad range of industrial and consumer end-use applications including flexible packaging, thermal lamination film, hot melt adhesive, USP class VI medical products and photovoltaic cells.  The business has manufacturing facilities in Edmonton, Canada, and is supported by expert technical service.  More information about Celanese EVA Performance Polymers Inc. is available at www.celanese-EVA.com.

Contact: Maureen Cochran
mcochran@particlesciences.com
610-861-4701


'/>"/>
SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
2. IBA Particle Therapys $20,000 Grant Helps Non-Profit Ease Costs for Children Traveling to Receive Proton Therapy
3. Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens
4. NovaSperse(SM) Nanoparticle Innovator, PharmaNova, Inc., Awarded Four Government Grants Toward Development of New Therapeutic Products Under Congressional Qualifying Therapeutic Discovery Project Initiative
5. Particle Sciences and SoluBest Enter into Technology Agreement
6. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
7. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
8. Researchers Use Nanoparticles as Destructive Beacons to Zap Tumors
9. Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate With Additional U.S. Patents
10. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
11. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DURHAM, N.C. , Feb. 8, 2016  Avista ... appointed Eric Setzer as Chief Financial Officer (CFO). ... over twenty years of experience in various roles within ... Avista Pharma, he served as the Executive Director of ... organization in Raleigh, NC . Previously, ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... 2016 Palatin Technologies, Inc. (NYSE MKT: ... therapeutics for the treatment of diseases with significant ... that the United States Patent and Trademark Office ... U.S. Patent Application Serial Number 14/313,258 (the ,258 ... treating female sexual dysfunction using the formulation and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth ... incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher ... make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase patient ... “What’s In Your Mouth?” campaign to inform dentists and patients about the possible ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
Breaking Medicine News(10 mins):